<DOC>
	<DOCNO>NCT02590289</DOCNO>
	<brief_summary>To assess pharmacokinetics 3 dos food effect single high dose BBI-5000 capsule healthy adult subject .</brief_summary>
	<brief_title>A Pharmacokinetic Study Evaluate BBI-5000 Capsules Food Effect Healthy Adult Subjects</brief_title>
	<detailed_description>This open-label , randomize , 4-period , 4-way crossover , 4-sequence study evaluate pharmacokinetics ( PK ) food effect BBI-5000 capsule healthy adult subject . Participating subject receive single oral dose BBI-5000 follow washout period 7-14 day dos . The treatment period follow 5-10 day follow-up period . PK PD assess blood sample 72 hour postdose . Safety assess collection vital sign , adverse event , physical examination , ECGs clinical laboratory test .</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<criteria>Nonsmoker Medically healthy 32.0 &gt; = BMI &gt; = 18.5 kg/m^2 Weight &gt; = 50 kg male Weight &gt; = 45 kg female For female childbearing potential : either sexually inactive 14 day prior first dose throughout study use acceptable birth control method dictate study Willing comply protocol understand study procedure outline ICF Subject mentally legally incapacitated significant emotional problem History presence medical psychiatric disease History illness might confound result study History presence alcoholism drug abuse History presence hypersensitivity idiosyncratic reaction study drug excipient History presence lactose intolerance Pregnant lactating female Seated blood pressure le 90/40 mmHg great 140/90 mmHg Seated heart rate lower 40 bpm high 99 bpm Unable refrain anticipates use drug Diet incompatible onstudy diet Donation blood significant blood loss within 56 day prior first study dose Participation another clinical trial within 28 day prior first study dose</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>